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Adjusted subcutaneous heparin was used for throm-
boembolism prophylaxis during 18 pregnancies in 16
women with an artificial heart valve. Oral warfarin was
replaced by subcutaneous heparin as soon as pregnancy
was confirmed. The dosage of heparin was adjusted to
maintain a partial thromboplastin time at 1.5 times the
control value and treatment was administered during
the first trimester and the last 3 weeks of gestation.
Warfarin was used between the 13th and 37th week.
There were no maternal thromboembolic complica-
Thromboembolism is a well known complication among
patients with artificial heart valves, and long-term prophy-
lactic anticoagulant therapy is necessary. Pregnancy, with
its associated "hypercoagulability state" due to increases
in coagulation factors II, VII, VIII and IX and inhibition
of fibrinolysis, further heightens the risk of maternal throm-
boembolic complications (1,2). Oral anticoagulants, with a
molecular weight of about 1,000, easily cross the placenta
and enter the fetal circulation. Their use is associated with
an increased incidence of fetal loss and development of
various congenital malformations (3-5) as well as bleeding
complications at delivery. Heparin does not cross the pla-
centa and its effect can be easily neutralized; it should there-
fore be the anticoagulant of choice during pregnancy. The
major drawback of heparin is the necessity for parenteral
adminstration. This is partially overcome by the introduction
of long-term self-administered subcutaneous heparin ther-
apy (6).
The substitution of self-adrninstered subcutaneous hep-
arin for oral warfarin during pregnancy was advocated by
many investigators (7-9). Our previous experience with
fixed low dose subcutaneous heparin during the first trimes-
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tions and none of the live-born infants showed congenital
malformations, indicating that this regimen is effective.
However, there were nine spontaneous abortions, in-
cluding fivethat occurred in the first 12weeks. The early
abortions were probably related to warfarin exposure
at the beginning of pregnancy. The preconception re-
placement of warfarin by heparin in these patients may
be indicated.
(J Am Coli CardioI1986;8:221-4)
ter and peripartum period showed that this regimen did not
adequately prevent maternal thromboembolism, in light of
the three major embolic events among 10 patients (10). Hull
et al. (11) concluded from their study on venous throm-
boembolism that an adjusted dose of subcutaneous heparin
to prolong the midinterval partial thromboplastin time to
1.5 times the control value is as effective as warfarin in
long-term treatment. This is especially important for preg-
nant women, who require an increasing dose of anticoag-
ulant agents as pregnancy progresses (12). The present study
was designed to test the efficacy of adjusted subcutaneous
heparin for thromboembolic prophylaxis in pregnant patients
with an artificial heart valve during the periods when the
use of oral anticoagulants is most hazardous.
Methods
Patient selection. From January 1983 to October 1985,
we observed 16 Chinese women with an artifical heart valve
during 18 pregnancies. Fourteen patients had mitral valve
replacement for rheumatic heart disease and the remaining
two had aortic valve replacement for aortic regurgitation of
rheumatic origin. The Bjork-Shiley tilting disc valve was
used in 11 patients, whereas the Starr-Edward ball valve
was implanted in the other 5. All but one patient had chronic
atrial fibrillation at the time of implantation. Seven were
primigravida; of the remaining nine, only two gave a history
of previous abortion before valve replacement (Table 1).
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Table 1. Summary of 18 Observed Pregnancies and Heparin Requirements in 16 Patients
Maximal Dose of
Subcutaneous Heparin
Prosthetic Valve Required (lU/Q8h)
Replacement Past Obstetric History 1st 3rd Outcome of
Case Site Type Preoperative Postoperative Trimester Trimester Pregnancy Comments
I Aortic BS Gzp\ S.OOO 6,SOO Live birth
2 Mitral BS 6,000 6.S00 Live birth
3 Mitral BS 7,000 7,SOO Live birth
4 Mitral BS GzPz 6.000 8,000 Live birth Infected hematoma
requiring drainage
S Mitral SE GIP I GzPz 7,SOO 9.S00 Live birth
6 Aortic BS GIP I 11,000 14,000 Live birth Continuous IV heparin
(IV) infusion during the
last 2 weeks
7 Mitral SE GIP I 8,SOO 11,000 Live birth Continuous IV heparin
(IV) during the last 2
weeks
8 Mitral SE 6.S00 7.S00 Live birth
9 Mitral BS G2PZ 6,SOO 7,000 Live birth
G3PJ 6,SOO Abortion in
18th week
10 Mitral BS GIP I 7,SOO Abortion in Massive intervillous
20th week placental hemorrhage
II Mitral BS 4,SOO Abortion in
8th week
12 Mitral SE GIP I 6.000 Abortion in
14th week
G2PI S,SOO Abortion in
12th week
13 Mitral BS S,SOO Abortion in
11th week
14 Mitral BS GIP I 7,000 Abortion in
14th week
IS Mitral SE 7,SOO Abortion in
8th week
16 Mitral BS Abortion in Aborted before
7th week commencement of
heparin
BS = Bjork-Shiley tilting disc valve; G = gravida; IV = intravenous; P = para; Q8h = every 8 hours; SE == Starr-Edwards ball valve.
Valve replacement was performed 16.2 ± 2.1 months (mean
± SD) before the observed pregnancies. The maternal age
at delivery or abortion was 26.8 ± 4.9 years. All patients
were regularly receiving warfarin therapy before pregnancy.
Anticoagulation protocol. As soon as the pregnancy
was confirmed (between 6 and 8 weeks after the last men-
strual period), administration of warfarin was immediately
discontinued. The mother was admitted to the hospital, where
treatment with subcutaneous heparin, 5,000 U every 8 hours,
was begun. This dose was adjusted daily until a midinterval
activated partial thromboplastin time, determined 4 hours
after the injection, of 1.5 times the control value was achieved
(automated activated partial thromboplastin time, General
Diagnostics, using activation by micronized silica and rabbit
brain partial thromboplastin). During this short hospital stay
the patient was also supervised by the nursing staff and
trained to perform subcutaneous injections. Before dis-
charge from the hospital, the patient was instructed to report
at once any symptom or sign suggestive of thromboembol-
ism, including transient or persistent loss of vision, weak-
ness or paresthesia of the limbs or progressive deterioration
in exercise capacity. She was then given a 2 week supply
of heparin for self-administration and was followed up at 2
week intervals at a special prosthetic valve clinic. The ac-
tivated partial thromboplastin time values were checked and
minor adjustments of the heparin dosage were continued to
maintain the target ratio.
During the 13th week of gestation, warfarin was rein-
troduced. The dose of warfarin was adjusted according to
the prothrombin time to maintain a British corrected ratio
of two to three times the control value. Subcutaneous hep-
arin therapy was discontinued when the target prothrombin
time was achieved. Warfarin therapy was then continued
until the 37th week of gestation, when it was replaced by
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adjusted subcutaneous heparin as described. At the onset of
labor, subcutaneous heparin was temporarily withdrawn . In
the absence of hemorrhagic complications, subcutaneous
heparin was resumed 4 to 8 hours after vaginal delivery.
Warfarin was resumed I week after delivery. Heparin was
discontinued when the target prothrombin time was again
achieved.
Results
Maternal complications. None of the 16 mothers de-
veloped signs or symptoms of thromboembolism during the
18 observed pregnancies. Four patients reported subjecti ve
deterioration in exercise capacity during the last trimester.
Other than mild ankle edema in two of these patients, there
were no clinical signs of heart failure. Excessive bleeding
was not encountered during vaginal delivery of the infants
alive at birth or during the uterine curettage procedure in
the three patients with incomplete abortion. However, minor
local bruises were present in all patients at the sites of
heparin injection. One patient developed a small abscess
over a hematoma on the thigh . This responded well to local
incision and drainage plus systemic antibiotic treatment.
Fetal complications. Nine spontaneous abortions oc-
curred (at the 7th, 8th, 11th, 12th, 14th, 18th and 20th
weeks of gestation [Table 1]). Histologic examination of
the placenta in Case 10 showed fresh intervillous thrombus
suggestive of recent hemorrhage. This occurred while the
patient was on warfarin therapy and the corresponding pro-
thrombin time checked on that admission was within the
therapeutic range at twice control. Examination of the other
placentas yielded normal findings . One mother had two
consecutive abortions at the 12th and the 14th week of
gestation, respectively. Another gave birth to one live infant
and later had a spontaneous abortion at the 18th week of
gestation. All infants alive at birth were delivered vaginally
at full term, except one delivered at the 37th week. The
average birth weight was 3,030 g. No congenital malfor-
mation was noted among the live-born infants.
Heparin dosage. The dosages of subcutaneous heparin
required to maintain the target activated partial thrombo-
plastin time were higher during the last 3 weeks of preg-
nancy than during the first trimester in all patients (Table
1). The average dose required during the first trimester was
6,330 U every 8 hours. This increased to 8,600 U during
the last 3 weeks. The highest dose given was 13,000 U
every 8 hours. In two patients, because of extensive bruising
at the injection sites, heparin was delivered intravenously
by a portable syringe pump during the last 2 weeks of
gestation.
Discussion
Adminstration of anticoagulant therapy during pregnancy
is problematic in patients with a valve prosthesis. Although
the use of xenografts in place of mechanical prostheses
seems to offer a solution for some patients , this is not par-
ticularly helpful for our local group of patients . Most of
them have rheumatic mitral valve disease complicated by
an enlarged left atrium and chronic atrial fibrillation. The
risk of thromboembolism will persist even after xenograft
replacement. Long-term anticoagulation is necessary irre-
spective of the type of artificial heart valve implanted (13).
In addition, the doubtful durability of the animal xenograft
is also a major concern among young patients of reproduc-
tive age (14 ,15) .
Feasibility of self-administration of heparin. The fea-
sibility of self-administered subcutaneous heparin therapy
is confirmed in our present study . All patients were able to
master the technique of subcutaneous injection after a short
period of training under supervision. However, despite the
use of rotating sites for injections and high concentration
preparations of heparin, multiple local bruises occurred in
all of our patients. This problem became increasingly trou-
blesome during the last few weeks of pregnancy when larger
does of heparin were required to achieve the target activated
partial thromboplastin time. In two patients requiring more
than 30,000 U heparin/day, we had to substitute continuous
intravenous infusion during the last 2 weeks before delivery .
We believe that continuous intravenous heparin infusion
during the last 3 weeks of pregnancy is more tolerable than
subcutaneous administration, especially for those patients
requiring more than 8,000 U of subcutaneous heparin every
8 hours. Our results also confirm the increasing heparin
requirement as pregnancy progresses. A continuous adjust-
ment of the heparin dosage according to the activated partial
thromboplastin time ratio is preferable to the single stage
adjustment advocated by Hull et al. (11) for venous throm-
bosis during pregnancy.
Efficacy of subcutaneous heparin. The efficacy of sub-
cutaneous heparin for thromboembolic prophylaxis was con-
firmed among pregnant patients with venous thrombosis in
several studies (11,16,17), but its effect in patients with an
artificial heart valve was not fully investigated before this
study . Although the earlier review by Hall et al. (4) of
published cases did not support the theoretic advantage of
heparin over warfarin in pregnant women, the patients' un-
derlying illnesses were not defined in that report and it is
difficult to apply their conclusion to our group of patients
with an artificial heart valve. Our previous experience (10)
with fixed low dose subcutaneous heparin (5,000 U at 12
hour intervals) during the first trimester and part of the third
trimester was disappointing, as three major thromboembolic
events occurred among 10 patients. In the present study,
with individual adjustment of heparin dosages according to
the activated partial thromboplastin time ratios and short-
ening of the interval between injections from 12 to 8 hours,
all maternal thromboembolic complications were elimi-
nated. This represents a major improvement over the fixed
low dose protocol.
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Limitations. The rate of fetal wastage with this anti-
coagulation protocol remains distressingly high at 50%. There
was no history of habitual abortion among the patients stud-
ied, although seven were primigravida with no previous
obstetric history. Five abortions occurred early, in or before
the 12th week of gestation. Our previous experience (18)
showed that women using warfarin during the first trimester
had a similar incidence of abortion (35%) and more than
63% of these occurred during the first trimester of gestation.
Because heparin does not cross the placenta and there was
no evidence of major maternal hemorrhagic complication
during heparin therapy, this treatment is unlikely to be the
cause of the excess spontaneous abortions. However, all of
our patients were receiving warfarin during the earliest stages
of pregnancy, and this agent may be an important factor in
the early abortions. To test this hypothesis, warfarin should
be replaced by subcutaneous heparin before conception,
when pregnancy is planned. This approach may make it
possible to lower the incidence of fetal wastage and at the
same time offer adequate thromboembolic prophylaxis in
mothers with an artificial heart valve.
The other four abortions occurred during the second
trimester of pregnancy while the patients were again re-
ceiving warfarin. There should be less likelihood of fetal
hemorrhage or malformation associated with the reintro-
duction of warfarin at this stage than during the first trimester
of pregnancy. However, the presence of fresh intervillous
thrombus in Case 10 confirmed the risk of controlled an-
ticoagulation even at this relatively late stage of gestation.
The continuous use of heparin throughout pregnancy not
only is inconvenient, but also may introduce new compli-
cations from long-term heparin therapy such as osteopo-
rosis. In addition, both Bennett and Oakley (19) and we
(10) have reported the development of thrombosis on arti-
ficial heart valves during pregnancy in patients receiving
continuous subcutaneous heparin therapy. Hence, the re-
introduction of warfarin during the second trimester will be
a necessary calculated risk.
We thank the Clinical Haematology Unit, Department of Pathology for
performing the activated partial thromboplastin time and prothrombin time
tests.
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